Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1867-1875

  Zhou, Yu ^a   Zhou, Quanbo ^a   Lin, Qing ^a   Chen, Ruiwan ^b   Gong, Yuanfeng ^a   Liu, Yimin ^a   Yu, Min ^a   Zeng, Bing ^a   Li, Kaiwen ^a   Chen, Rufu ^a   Li, Zhihua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABO blood group; bile duct cancer; epidemiology; hepatitis

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CHINA; CONTROLLED STUDY; DISEASE COURSE; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNIVERSITY HOSPITAL;

ABO BLOOD GROUP; BILE DUCT CANCER; EPIDEMIOLOGY; HEPATITIS;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BLOOD GROUP ANTIGENS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CHINA; CHOLANGIOCARCINOMA; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84881556027     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28196     Document Type: Article

References (41)

1. Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42: 253-60.
2. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-20.
3. Patel T,. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
4. McLean L, Patel T,. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States (2006). Liver Int 2006; 26: 1047-53.
5. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
6. Hsing AW, Gao YT, Devesa SS, et al. Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer 1998; 75: 368-70.
7. Tyson GL, El-Serag HB,. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-84.
8. Rustagi T, Dasanu CA,. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer 2012; 43: 137-47.
9. Dehesa-Violante M, Nunez-Nat eras R,. Epidemiology of hepatitis virus B and C. Arch Med Res 2007; 38: 606-11.
10. Melzer D, Perry JR, Hernandez D, et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008; 4: e1000072.
11. Paré G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association stud y of 6,578 women. PLoS Genet 2008; 4: e1000118.
12. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520-8.
13. Dabelsteen E, Gao S,. ABO blood-group antigens in oral cancer. J Dent Res 2005; 84: 21-8.
14. Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172: 1280-5.
15. Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101: 424-31.
16. Gates MA, Wolpin BM, Cramer DW, et al. ABO blood group and incidence of epithelial ovarian cancer. Int J Cancer 2011; 128: 482-6.
17. Wang DS, Chen DL, Ren C, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer 2012; 131: 461-8.
18. Dabelsteen E,. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996; 179: 358-69.
19. Hakomori S,. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999; 1473: 247-66.
20. Cordon-Cardo C, Reuter VE, Finstad CL, et al. Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma. Cancer Res 1989; 49: 212-18.
21. Halloran MM, Carley WW, Polverini PJ, et al. Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol 2000; 164: 4868-77.
22. Jick H, Slone D, Westerholm B, et al. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-42.
23. Bryne M, Eide GE, Lilleng R, et al. A multivariate study of the prognosis of oral squamous cell carcinomas. Are blood group and hemoglobin new prognostic factors? Cancer 1991; 68: 1994-8.
24. Dresler CM, Ritter JH, Wick MR, et al. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg 1995; 59: 1069-73.
25. Moldvay J, Scheid P, Wild P, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 1125-34.
26. Chen R, Zou S, Zhao X,. The expression of hepatitis C virus in hilar cholangiocarcinoma and implication. Chin J Exp Surg 2000; 17: 223-5.
27. Yin F, Chen B,. Detection of hepatitis C virus RNA sequences in hepatic portal cholangiocarcinoma tissue by reverse transcription polymerase chain reaction. Chin Med J 1998; 111: 1068-70.
28. Wang WL, Gu GY, Hu M,. Expression and significance of HBV genes and their antigens in human primary intrahepatic cholangiocarcinoma. World J Gastroenterol 1998; 4: 392-6.
29. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
30. Barajas M, Franchi F, Clavel C, et al. Multipotent adult progenitor cells (MAPC) contribute to hepatocarcinoma neovasculature. Biochem Biophys Res Commun 2007; 364: 92-9.
31. Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-Associated intra-hepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100: 1765-70.
32. Zhou H, Wang H, Zhou D, et al. Hepatitis B virus-Associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 2010; 46: 1056-61.
33. Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol 2011; 18: 1258-66.
34. Cardinale V, Wang Y, Carpino G, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology 2011; 54: 2159-72.
35. Carpino G, Cardinale V, Onori P, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat 2012; 220: 186-99.
36. El-Serag HB, Rudolph KL,. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
37. Yu MW, Chen CJ,. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993; 53: 790-4.
38. Wu MH, Ma WL, Hsu CL, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010; 2: 32-5.
39. Farinati F, De Maria N, Marafin C, et al. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor? Eur J Gastroenterol Hepatol 1995; 7: 145-50.
40. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-44.
41. Garratty G,. Blood groups and disease: a historical perspective. Transfus Med Rev 2000; 14: 291-301.